Systems and methods for promoting trans-splicing
AssigneeTacit Therapeutics, Inc.
InventorDavid Allen NELLES
Life of this patent
Estimating the term…
Abstract
Described herein are compositions systems and methods for promoting trans-splicing. In some examples, the system may comprise a nucleic acid molecule. The nucleic acid molecule may encode an exonic sequence. The system may further comprise a tethering fusion protein. The tethering fusion protein may promote an association of the exonic sequence and a target RNA or portion thereof.
Claims182
A system for trans-splicing, comprising:
- a. a nucleic acid molecule encoding:
- i. an exonic sequence;
- and
- ii. at least one intronic domain configured to promote insertion of said exonic sequence into a target RNA molecule;
- and
- iii. one or more binding domains configured to interact with an RNA-binding protein, wherein said RNA-binding protein is encoded by one or more human-derived sequences;
- and
- b. said RNA binding protein, which is configured to insert said exonic sequence into said target RNA molecule.
The system for trans-splicing of any one of the preceding claims, further comprising an engineered small nuclear RNA derived or isolated from a U1 snRNA gene that promotes trans-splicing between a target RNA and said exonic sequence.
The system for trans-splicing of any one of the preceding claims, wherein said nucleic acid molecule encodes one or more binding sites for the RNA-binding domain.
The system for trans-splicing of any one of the preceding claims, wherein said nucleic acid molecule further encodes a sequence that promotes accumulation of the exonic sequence molecule in the cellular nucleus.
The system for trans-splicing of any one of the preceding claims, wherein said nucleic acid molecule further encodes a 3′ untranslated region that increases the stability of the trans-splicing molecule.
The system for trans-splicing of any one of the preceding claims, wherein said nucleic acid molecule further encodes a 5′ untranslated region that increases the stability of the trans-splicing molecule.
The system for trans-splicing of any one of the preceding claims, wherein said nucleic acid molecule further encodes a gene expression-enhancing element.
The system for trans-splicing of any one of the preceding claims, wherein said nucleic acid molecule further encodes a heterologous promoter.
The system for trans-splicing of any one of the preceding claims, wherein said system for trans-splicing lacks a CRISPR-associated protein.
A vector comprising the system for trans-splicing of any one of the preceding claims.
A method for treating a disease comprising administering to a patient in need of a therapeutically effective amount of a treatment comprising a nucleic acid molecule according to any one of the preceding claims.
A system for trans-splicing, comprising:
- a. a nucleic acid molecule encoding:
- i. an exonic sequence;
- and
- ii. at least one intronic domain configured to promote insertion of said exonic sequence into a target RNA molecule;
- and
- b. a protein configured to insert said exonic sequence into said target RNA molecule,
- wherein said system for trans-splicing lacks a CRISPR-associated protein.
A nucleic acid molecule encoding:
- a. an exonic sequence;
- b. at least one intronic domain configured to promote insertion of said exonic sequence into a target RNA molecule;
- and
- c. one or more binding domains that interact with an RNA-binding protein, wherein said RNA-binding protein is encoded by one or more human-derived sequences, and wherein said RNA-binding protein is configured to interact with a transcriptional or spliceosomal enzyme coupled to said target RNA.
A system for trans-splicing, comprising:
- a. a nucleic acid molecule encoding:
- i. an exonic sequence;
- ii. at least one intronic domain configured to promote insertion of said exonic sequence into a target RNA molecule;
- and
- iii. one or more binding domains that interact with an RNA-binding protein, wherein said RNA-binding protein is encoded by one or more human-derived sequences;
- and
- b. a tethering protein that promotes the association of said exonic sequence and said target RNA molecule, and wherein said tethering protein is configured to bind to said one or more binding domains.
A method of associating an exonic sequence with a target RNA, the method comprising:
- a. providing a nucleic acid encoding:
- i. an exonic sequence;
- ii. at least one intronic domain configured to promote insertion of said exonic sequence into a target RNA molecule;
- and
- iii. one or more binding domains that interact with a tethering protein;
- and
- b. binding a tethering protein to said one or more binding domains and to said target RNA molecule to associate said exonic sequence with, said target RNA molecule.
A method of associating an exonic sequence with a target RNA, the method comprising:
- a. providing a nucleic acid molecule encoding:
- i. a exonic sequence;
- and
- ii. at least one intronic domain configured to promote insertion of said exonic sequence into a target RNA molecule;
- and
- b. binding a tethering protein to said target RNA molecule and said exonic sequence to associate said exonic sequence with said target RNA molecule, wherein said trans-splicing molecule does not associate with a CRISPR enzyme.
A system for trans-splicing comprising a nucleic acid encoding an exonic sequence and a tethering fusion protein, wherein the tethering fusion protein promotes the association of the exonic sequence and a target RNA.
A vector comprising the system for trans-splicing of any one of claims 142-160.
A method of targeting an exonic sequence to a target RNA, the method comprising:
- a. providing a nucleic acid encoding said exonic sequence;
- b. providing said target RNA;
- and
- c. using a tethering fusion protein to associate said exonic sequence and said target RNA.
Dependencies are inferred from the claim text.